Canadian and Israeli researchers join forces for new research program

Download PDF Copy

Oct 30 2017

Backgrounder

The Joint Canada-Israel Health Research Program is a seven-year, CA$35 million partnership between the Azrieli Foundation, Canada's International Development Research Centre, the Canadian Institutes of Health Research, and the Israel Science Foundation that draws on the scientific strengths of Canadian and Israeli researchers in the broad field of biomedicine. It is expected to fund up to 30 collaborative projects involving researchers from Canada and Israel, as well as from low- and middle-income countries.

Selected Cancer Research Projects

In October 2016, the partners launched the 3^rd call for research proposals in the field of cancer. The proposals were evaluated by an international committee, Chaired by Prof. Edward Harlow from the Department of Biological Chemistry & Molecular Pharmacology, Harvard Medical School. Six world-class teams were selected from among 56 proposals and will receive funding totaling up to C$ 7 million over the next three years.

The following list of projects is in alphabetical order according to the Canadian Nominated Principal Investigators' last names.

NOTCH as master regulator of breast cancer subtype and intratumoral heterogeneity
- Researchers: Sean Egan (Hospital for Sick Children), Ittai Ben-Porath (Hebrew University of Jerusalem), Anaapoorni Rangarajan (Indian Institute of Science)
The role of IL6 in liver cancer linked to metabolic liver disease
- Researchers: Jennifer Estall (IRCM), Eitan Galun (Hadassah Medical Centre), Mehmet Ozturk (Bilkent University, Turkey)
Targeting senescence cells in pancreatic cancer
- Researchers: Gerardo Ferbeyre (Université de Montréal), Valery Krizhanovsky (Weizmann Institute of Science), Paloma Kalegari (Brazil)
Systematic and comprehensive analysis of mutant p53 proteins in lung cancer in vitro and in vivo
- Researchers: Daniel Schramek (Lunenfeld-Tanenbaum Research Institute), Moshe Oren (Weizmann Institute of Science), Patricia Aston-Prola (Universidade Federal do Rio Grande do Sul, Brazil) and Nicolas González Foutel (Universidad San Martin, Argentina)
Understanding the role of type 1 interferon in resistance to cancer immunotherapy
- Researchers: David Spaner (Sunnybrook Research Institute - University of Toronto); Gideon Schreiber (Weizmann Institute of Science); You-Jun Li (Jilin University - China)
The role of epitranscriptome and translational dysregulation in cancer
- Researchers: Ivan Topisirovic (McGill University), Dan Dominissini (Sheba Medical Center), Glaucia Noeli Maroso Hajj (AC Camargo Cancer Centre, Brazil)